Curetis Nv. Curetis NV is a Germany-based company that is engaged in the biotechnology sector. It specializes in molecular diagnostics, detection of antibiotic resistance, as well as diagnosis of severe infectious diseases. The Company's main product is Unyvero, a diagnosis system that uses a variety of cartridges to detect diseases such as pneumonia or implant and tissue infections, and can also be used following operations and transplants, as well as for burn wounds and diabetic feet. The diagnosis system consists of the Unyvero L4 Lysator for the lysis of native patient samples, the Unyvero A50 Analyzer for handling and reading out the cartridge, as well as the Unyvero C8 Cockpit as user interaction and control panel, and is equipped with device-specific software. The Company's products can be used in laboratories, as well as in hospitals.
Ford US Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.